Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 22;23(1):62.
doi: 10.1186/s13054-019-2352-6.

Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement

Marion Wiegele  1 , Herbert Schöchl  2   3 , Alexander Haushofer  4 , Martin Ortler  5   6 , Johannes Leitgeb  7 , Oskar Kwasny  8 , Ronny Beer  9 , Cihan Ay  10 , Eva Schaden  1
Affiliations

Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement

Marion Wiegele et al. Crit Care. .

Abstract

There is a high degree of uncertainty regarding optimum care of patients with potential or known intake of oral anticoagulants and traumatic brain injury (TBI). Anticoagulation therapy aggravates the risk of intracerebral hemorrhage but, on the other hand, patients take anticoagulants because of an underlying prothrombotic risk, and this could be increased following trauma. Treatment decisions must be taken with due consideration of both these risks. An interdisciplinary group of Austrian experts was convened to develop recommendations for best clinical practice. The aim was to provide pragmatic, clear, and easy-to-follow clinical guidance for coagulation management in adult patients with TBI and potential or known intake of platelet inhibitors, vitamin K antagonists, or non-vitamin K antagonist oral anticoagulants. Diagnosis, coagulation testing, and reversal of anticoagulation were considered as key steps upon presentation. Post-trauma management (prophylaxis for thromboembolism and resumption of long-term anticoagulation therapy) was also explored. The lack of robust evidence on which to base treatment recommendations highlights the need for randomized controlled trials in this setting.

Keywords: Anticoagulation reversal; Coagulation management; Idarucizumab; Intracranial hemorrhage; Non-vitamin K antagonist oral anticoagulant (NOAC); Platelet inhibitors; Prothrombin complex concentrate (PCC); Traumatic brain injury; Vitamin K antagonist (VKA).

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

MW reports speaker fees and travel reimbursement from CSL Behring. HS reports speaker fees and study grants from CSL Behring, Werfen/TEM International, Böhringer Ingelheim RCV GmbH & Co KG Austria, and Haemonetics Corporation. AH reports personal fees (consulting services and/or speaker honoraria) from Boehringer Ingelheim RCV GmbH & Co KG Austria, Novo Nordisc Pharma GmbH Austria, and Daiichi-Sankyo Austria GmbH. MO reports speakers’ honoraria and symposium support from Baxalta Österreich GmbH. RB reports personal fees (consulting services and speaker honoraria) from Boehringer Ingelheim RCV GmbH & Co KG Austria. CA reports personal fees (consulting services and/or speaker honoraria) from Bayer Austria, Boehringer Ingelheim RCV GmbH & Co KG Austria, Daiichi-Sankyo Austria GmbH, and Shire Austria GmbH. ES reports speaker fees from Baxalta Österreich GmbH, Boehringer Ingelheim RCV GmbH & Co KG Austria, Daiichi-Sankyo Austria GmbH, and Shire Austria GmbH. The other authors declare that they do not have competing interests. The authors did not receive any financial compensation related to this manuscript.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Best practice recommendations for the diagnosis and treatment of adult patients experiencing traumatic brain injury during treatment with oral anticoagulants
See this image and copyright information in PMC

Comment in

References

    1. Mauritz W, Brazinova A, Majdan M, Leitgeb J. Epidemiology of traumatic brain injury in Austria. Wien Klin Wochenschr. 2014;126:42–52. - PMC - PubMed
    1. Peeters W, van den Brande R, Polinder S, Brazinova A, Steyerberg EW, Lingsma HF, et al. Epidemiology of traumatic brain injury in Europe. Acta Neurochir. 2015;157:1683–1696. - PMC - PubMed
    1. Herou E, Romner B, Tomasevic G. Acute traumatic brain injury: mortality in the elderly. World Neurosurg. 2015;83:996–1001. - PubMed
    1. Majdan M, Plancikova D, Brazinova A, Rusnak M, Nieboer D, Feigin V, et al. Epidemiology of traumatic brain injuries in Europe: a cross-sectional analysis. Lancet Public Health. 2016;1:e76–e83. - PubMed
    1. Frontera JA, Lewin JJ, 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of Antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care society and Society of Critical Care Medicine. Neurocrit Care. 2016;24:6–46. - PubMed

Publication types

MeSH terms